Navigation Links
Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
Date:4/30/2008

- Final study report expected in June 2008 -

MORRISTOWN, N.J., April 30 /PRNewswire/ -- Vicus Therapeutics, LLC, a biopharmaceutical company focused on oncology supportive care, announced today the completion of the last patient visit in its study VT1-CAX-001, a Phase 2 trial of VT-122. The compound was tested for the treatment of cachexia in weight losing subjects with Stage IV, non-small cell lung cancer (NSCLC). The Phase 2 clinical trial was conducted in India and the final study report is expected in June 2008.

A total of 59 subjects were deemed eligible for this multi-center, randomized, open-label controlled Phase 2 study in weight losing Stage IV NSCLC patients not on chemotherapy. The 12 subjects randomized to the control arm received best supportive care and the 25 subjects randomized to the treatment arms received best supportive care and one of two doses of VT-122. Twenty-two of the screened subjects were not randomized. The primary efficacy endpoints assessed were maintenance of muscle mass (lean body mass) and function (grip strength). Efficacy endpoints of total body weight and quality of life were also assessed. Assessments for safety and efficacy were continued for 12 weeks after randomization. No treatment related serious adverse events were reported.

"The successful completion of the Phase 2 study marks an important milestone in the development of VT-122," said John Maki, President and Chief Executive Officer of Vicus Therapeutics. "Based on favorable analysis of the preliminary data, we expect to initiate discussions with prospective partners to secure resources to maximize the potential of VT-122."

About Cachexia and VT-122

Cachexia is a debilitating, progressive muscle wasting condition manifested by unintentional weight loss, muscle weakness, anemia, fatigue, and death. In advanced cancer patients, the prevalence of cachexia increases from 50% at diagnosis to more than 80% prior to death. T
'/>"/>

SOURCE Vicus Therapeutics, LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
3. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
7. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
8. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
9. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
10. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
11. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- Environmental health advocates hope that U.S. FDA ... of bisphenol A (BPA), a synthetic sex hormone ... other illnesses, in time for Christmas. ,, ... scientist, Natural Resources Defense Council : "Just ... advice, FDA must rely on the advice of ...
(Date:12/14/2009)... CLAREMONT, Calif., Dec. 14 The ... College today released the analysis of social ... companies world-wide. The report contains a compilation ... the environmental and social reporting of the ... intent, and performance for both environmental and ...
(Date:12/14/2009)... Mass., Dec. 14 According to Millennium ... technology market intelligence, increased use of safety devices ... will be a key driver of the enteral ... Europe. MRG,s new US and European Markets ... that the giving set segment will experience the ...
Breaking Medicine Technology:Toxic Chemical bisphenol A Still Not Banned By FDA; Schumer, Gillibrand Call for Ban; Govt Official Warns Public 2New Report Grades Sustainability Reporting of Top Pharmaceutical Companies 2New Report Grades Sustainability Reporting of Top Pharmaceutical Companies 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Abbott Completes Visiogen Acquisition 5625 1Abbott Completes Visiogen Acquisition 5625 2Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27 2009 5620 1Penn team uses self assembly to make molecule sized particles with patches of charge 10447 1Penn team uses self assembly to make molecule sized particles with patches of charge 10447 2
(Date:12/14/2009)... now provides in-home caregivers who have been certified by the ... therapy, caregiver, and hospice services to San Francisco Bay Area ... ... (PRWEB) December 14, 2009 -- Professional HealthCare at Home, the ... care, including nursing, rehab, personal caregiver and hospice services, has ...
(Date:12/14/2009)... 14 Josie Raper, a 29 year-old mother from ... months with the help of the Dr. Siegal,s COOKIE DIET® ... Joy Fit Club segment on NBC,s Today Show. The Joy ... airs twice a month and salutes those who have lost ... and has kept it off for two years. ,, "The ...
(Date:12/14/2009)... Only about one in 2,000 people in the United ... of the unfortunate few. , Ms. Wilcox,s tumor was a ... those problems were mistaken for blocked sinuses. , "For several ... my nose," recalled the resident of Goldthwaite, a town of ... "I felt a fullness, but I didn,t take that as ...
(Date:12/14/2009)... the December issue of Mayo Clinic Proceedings , ... This retrospective study is the largest ever conducted in ... a serious disorder that disrupts the body,s normal production ... the bone marrow, leading to severe anemia, weakness, fatigue ... "In the past 20 years, management of primary myelofibrosis ...
(Date:12/14/2009)... long-term solution, researchers say , , MONDAY, Dec. 14 ... dislocations can benefit from a procedure that "sculpts" ... cadavers, new research suggests. , The study, ... American Journal of Sports Medicine , finds that ... that stabilize or reconstruct a shoulder joint by ...
Breaking Medicine News(10 mins):Health News:Caregivers with Professional HealthCare at Home Now Certified by the Alzheimer's Association 2Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 2Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 3Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 4Health News:Minimally invasive surgery removes sinus tumor without facial disfiguration 2
... CITY, Feb. 11 Two Little Hands Productions --,creators ... public television,show designed to teach babies, toddlers and young ... debut its second season at this,year,s Toy Fair 2008 ... http://www.newscom.com/cgi-bin/prnh/20080211/LAM029 ), Like the original, series ...
... Feb. 11 MedThink Communications, an,innovator in ... has been retained by Salix Pharmaceuticals, Inc, ... product under development, an,orally disintegrating form of ... to market the orally disintegrating,metoclopramide tablet and ...
... found that one in twenty breast cancer web pages ... complementary or alternative medicine were fifteen times more likely ... the March 15, 2008 issue of CANCER, a peer-reviewed ... patients consult clinicians before taking action on breast cancer ...
... researchers led by Fred Hutchinson Cancer Research Center has ... ovarian tumors become resistant to treatment with commonly used ... describe their research online Feb. 10 in the journal ... of ovarian-cancer cells from women with inherited mutations in ...
... & Shop,Supermarket Company, following a voluntary recall by Chattem, ... from sale. Chattem,is recalling these products based on consumer ... as skin irritation resulting from consumer use,or possible misuse ... of the following Icy Hot Heat Therapy products,are affected ...
... forests, point to sedentary society, , , FRIDAy, Feb. 8 (HealthDay News) ... could go to connect with nature, but that healthy ideal may ... week,s issue of the Proceedings of the National Academies of ... may be down by as much as 25 percent since 1987. ...
Other Medicine News:Health News:Two Little Hands Productions, Creators of Popular Children's TV Series Signing Time, Debuts Second Season at This Year's Toy Fair 2008 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 3Health News:Predictors of inaccurate online breast cancer information 2Health News:Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy 2Health News:Stop & Shop Alerts Customers to Voluntary Recall of Chattem Icy Hot Heat Therapy Products 2Health News:Americans Abandoning National Parks 2Health News:Americans Abandoning National Parks 3
The complete performance package. Precision handling. Stable platform for device delivery. Enhanced backup support. Unique braid technology. Improved curve retention. Smooth PTFE liner....
The soft tip sheath design for smooth delivery and retrieval of Constellation advanced mapping basket catheters....
Fast-Cath, Maximum, Maximum Xtra, and Maximum ACT introducers represent the largest line of standard and specialty hemostasis introducers in the world....
A steerable diagnostic catheter with optimal maneuverability...
Medicine Products: